What is MaxCyte, Inc. (MXCT)?

MaxCyte, Inc. (MXCT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of MXCT?

The current price of MXCT is $1.54. Prices are updated in real time on Stocks360.

What is MXCT's price-to-earnings (PE) ratio?

MXCT's trailing twelve-month PE ratio is -4.61, based on current price and earnings per share data available on Stocks360.

What is MXCT's market capitalization?

MXCT's market capitalization is $158,937,563.00, placing it in the small-cap tier.

MaxCyte, Inc. (MXCT)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.54

Market Cap

$158.94M

PE (TTM)

-4.61

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.49

Day Range

$1.51 – $1.64

52-wk Range

$0.64 – $1.81

Avg Volume

N/A

Volume

1.58M

MaxCyte, Inc. (MXCT) is a publicly traded company in the Healthcare sector. Latest price: $1.54. Market cap $158.94M. Trailing PE -4.61. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $1.55 2026-10-27 · $1.54 (-0.65%)

Earnings

Most Recent

Aug 12, 2026

EPS $-0.08 vs est. $-0.09

Beat by $0.01

Next Earnings

Nov 10, 2026

EPS estimate $-0.08

Proprietary Signals

Signal snapshot temporarily unavailable.

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.61×
P/S (TTM)	5.12×
P/B	1.04×
P/FCF (TTM)	-6.68×
EV / EBITDA	-5.23×
EV / Sales	5.19×
Earnings Yield	-21.66%
Free Cash Flow Yield	-14.97%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$161.15M
Revenue (TTM)	$31.05M
Net Income (TTM)	-$34.43M
Free Cash Flow (TTM)	-$23.79M
Net Debt	$2.21M
Working Capital	$111.38M
Gross Margin	79.43%
Operating Margin	-111.63%
Net Margin	-114.77%
Return on Equity	-21.01%
Return on Invested Capital	-19.66%